Register
Login:
Share:
Email Facebook Twitter

Please take part in our survey It takes 2 minutes and you could win an Apple iPad Air 2 (Terms and conditions apply). Dismiss Message




Quick Poll
QUICK POLL >
Do you invest in funds?




Add Scancell Holdings to quick picks

Scancell Holdings Share Price (SCLP)



Share Price Information for Scancell Holdings (SCLP)


Share Price: 33.00Bid: 32.00Ask: 34.00Change: -0.25 (-0.75%)Faller - Scancell Hldgs
Spread: 2.00Spread as %: 6.25%Open: 33.00High: 33.25Low: 33.00Yesterday’s Close: 33.25
InfoCFDs vs Share Trading - Download your Free Guide from London South East Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Scancell Holdings Plc Ord 0.1P

Scancell Holdings is listed in the FTSE AIM All-Share
Scancell Holdings is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
33.00

Share Price SpacerBid
32.00

Share Price SpacerAsk
34.00

Share Price SpacerChange
-0.75%-0.25

Share Price SpacerVolume
77,962

Share Price SpacerOpen
33.00

Share Price SpacerHigh
33.25

Share Price SpacerLow
33.00

Share Price SpacerClose
33.25

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 224.95m £74.23m 15,000

52 Week High 40.00 52 Week High Date 30-OCT-2014
52 Week Low 28.00 52 Week Low Date 6-AUG-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8 76,962 1,000 -32.039 -1.03 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

30-Jan-15
16:21:05
32.62
6,168
Sell* 
32.00
34.00
2,012
Trade Type:
Ordinary

30-Jan-15
15:31:11
32.62
1,006
Sell* 
32.00
34.50
328.16
Trade Type:
Ordinary

30-Jan-15
12:50:47
32.62
3,000
Sell* 
32.00
34.50
978.60
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Scancell Holdings trades >>

Directors Deals for Scancell Holdings (SCLP)
Trade DateActionNotifierPriceCurrencyAmountHolding
10-Dec-13Notification of Holding
Trade Notifier Information for Scancell Holdings
Lindy Durrant held the position of CEO at Scancell Holdings at the time of this trade.
 Lindy Durrant
000
10-Dec-13Notification of Holding
Trade Notifier Information for Scancell Holdings
Richard Goodfellow held the position of Joint CEO at Scancell Holdings at the time of this trade.
 Richard Goodfellow
000
21-Oct-13Sell
Trade Notifier Information for Scancell Holdings
Lindy Durrant held the position of CEO at Scancell Holdings at the time of this trade.
 Lindy Durrant
30GBX100,0000
View more Scancell Holdings directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 21:13
ratcliffewriter
RE: milkthatcow
33.00
Strong Buy

Following on from boom's post I think it was Lindy Durrant (or one of the scancell team as I remember) who made the point that if you can locate a site to inject it then you can reach it to cut it out. It is the inoperable sites or the unseen traces which scancell's products can clear out, which gives them a clear lead in effectiveness over oncosec.
Today 21:11
Bibio
C7
33.00
No Opinion

Hey buddy . . . . . I don't remember a total figure re total II holdings, except perhaps the reuters website that was showing incorrect data. Then again - brain frazzle seems to be on the increase in my case . . . . . . memory on the fritz. O/T - bit of a showdown at the bridge tomorrow. ATB
Today 21:01
boomorbust
milkthatcow
33.00
No Opinion

There have been many previous discussions on this bb about OncoSec. If you google OncoSec and Puritas you should get some info. I know that both Wild, Crumbs and myself (and probably many others) have also posted in the past about the similarities and differences between the two, again you should be able to google these. I would just make a couple of points. Firstly, the last time I looked, OncoSec hadn't posted any survival data on any of its trials. This may have now changed. Secondly the Companies are aiming for a different markets. Scancell are intending for SCIB1 primarily to be a treatment for resected patients - OncoSec are unable to operate in this market. OncoSec's vaccine has to be injected directly into the lesion and therefore can't be used on resected patients .
Today 20:51
CHELSEA7
Bibio
33.00
Strong Buy

Was it not your goodself who mentioned to me a couple of weeks back that the iis had 63% of Scancell. Milk that cow, likewise Inanaco has explained big differences between the two. I am sure he will write up a relevant post. You say...................... It is believed this will be the historical winner over Scancell, which I was concerned to hear. I am not very updated on OncoSec if someone could help me out it would be great. Could you kindly expand on who said that.
Today 20:49
Wildforce
Milk
33.00
Strong Buy

I'll save you some trouble .. " All 14 study patients produced a melanoma-specific T-cell response to treatment " I make that 100% ? Take care ..
Today 20:40
Wildforce
Actually
33.00
Strong Buy

39% ?? Look up scancells scib1 part 2 ....?

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Scancell Holdings (SCLP) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.